Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.43 |
| ▸ | EBP | Q15125 | 2/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4763684 | 0.94 | TGFBR1 (0.45) | SMN1; SMN2KCNH2TGFBR1ACVR1KDM4E | |
| SCHEMBL4763764 | 0.90 | TGFBR1 (0.49) | SMN1; SMN2TGFBR1ACVR1KDM4EALDH1A1 | |
| SCHEMBL4768736 | 0.89 | MEN1 (0.42) | SMN1; SMN2KCNH2TGFBR1ACVR1KDM4E | |
| SCHEMBL4774671 | 0.88 | TGFBR1 (0.41) | SMN1; SMN2KCNH2TGFBR1ACVR1SIGMAR1 | |
| SCHEMBL4763891 | 0.86 | KDM4E (0.53) | TGFBR1ACVR1KDM4EALDH1A1TDP1 | |
| SCHEMBL4763699 | 0.85 | TGFBR1 (0.51) | TGFBR1ACVR1KDM4EALDH1A1TDP1 | |
| SCHEMBL4764246 | 0.84 | BACE1 (0.51) | TGFBR1ACVR1ALDH1A1SIGMAR1 | |
| SCHEMBL7161609 | 0.84 | HCRTR1 (0.51) | ALDH1A1 | |
| SCHEMBL7160532 | 0.84 | KDM4E (0.51) | TGFBR1ACVR1KDM4EALDH1A1TDP1 | |
| SCHEMBL4773743 | 0.84 | TGFBR1 (0.53) | TGFBR1ACVR1KDM4EALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1400513-B1 | UNSYMMETRICAL CYCLIC DIAMINE COMPOUND | KOWA CO (JP) | 2008-01-09 | — | — | EP | disclosed |
| EP-1400513-A1 | UNSYMMETRICAL CYCLIC DIAMINE COMPOUND | Kowa Co., Ltd. (JP) | 2004-03-24 | — | — | EP | disclosed |
| US-6552188-B2 | Inhibit cell adhesion and cell infiltration; useful treating asthma, allergies, rheumatic diseases, arteriosclerosis, and inflammation; 2-(3,4,5-trimethoxyphenyl),4-((4-substituted piperazin-1-yl)methyl)pyridine compounds | KOWA CO., LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| US-20030022887-A1 | Unsymmetrical cyclic diamine compound | KOWA CO., LTD. (JP) | 2003-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022887-A1 | Unsymmetrical cyclic diamine compound | H1-0, DDAH1, AOC1 | SMN1; SMN2 2573/4885KCNH2 127/4885TGFBR1 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.